AEterna Zentaris, Inc. (AEZS)
NGM · Common · CUSIP 007975402
Last Price•••.••
Current Yield•.••%
Yield to Call•.••%
Yield to Worst•.••%
Free registration unlocks the quote, yield calculations, price chart and full fundamentals for AEZS and every other security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Common Stock
CUSIP
007975402 (prev. 007975303 )
Market Cap
Micro Cap
Previous Symbol
AELA (changed 6/3/2004)
Previous Name
aEterna Laboratories, Inc.
Business: AEterna Zentaris, Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing, macimorelin, an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare endocrine disorder.
Notes: November 18, 2015 - AEterna Zentaris Inc. (AEZS) will effect a one for one hundred (1-100) reverse split of its common stock. The reverse split will be effective at the opening of business on Friday, November 20, 2015. In conjunction with the reverse split, the CUSIP number will change to 007975402.

Company Contact

CEO
Klaus Paulini
CFO
Giuliano La Fratta
Headquarters
222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7
Phone
843-900-3223
Fax
418-652-0881
Investor Relations
Jenene Thomas, JTC Team · 833-475-8247 · aezs@jtcir.com
Email Form
Contact Form »
SEC EDGAR Filings
View filings »
SEDAR+ Filings
Go to SEDAR+ »